ZYBERNO
Stock Report
Updated Aug 31, 2026

Indaptus Therapeutics, Inc. (INDP)

Healthcare • NASDAQ

$1.14

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Indaptus Therapeutics, Inc. (INDP) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-302.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-288.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Indaptus Therapeutics, Inc. (INDP) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.14
Market Cap:$132.39M

Valuation Multiples (2)

P/B Ratio:11.64x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$124.85M

Price Action & Momentum (3)

Momentum Percentile:3 / 100
% of 52-Week High:13.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-203.5%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$1.15K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:12.27x
Quick Ratio:12.27x
Cash Ratio:12.27x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:6,938,394.00
Cash And Cash Equivalents:7,553,820.00
Long Term Debt:$8.69K
Net Debt:-$7.54M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$14.77M

Bottom Line Performance (3)

-$15.42M
Income Before Tax:-$7.42M
Ebitda Ttm:-14,771,910.00

Operating Expenses (5)

Operating Expenses:14,772,645.00
R And D Expense:5,217,266.00
Sga Expense:9,555,379.00
Income Tax Expense:$13.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.99M
Current Assets:$7.55M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:615,426.00
Current Liabilities:615,426.00
Long Term Debt:$8.69K
Short Term Debt:$8.69K

Equity & Capital (3)

Equity:$11.37M
Retained Earnings:-$85.62M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:508,877.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:227,180.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.79M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$5.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,396,888.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:735.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-12.42
-$12.42
Earnings Per Share Ttm:-$0.13

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.13

Book Value & Capital (2)

Book Value Per Share:$0.10
Cash Per Share:0.07

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-45.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:INDP
Company Name:Indaptus Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:116.13M
Shares Outstanding Basic:116.13M
Shares Outstanding Diluted:116.13M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 06:09:06 UTC
Data Timestamp:2026-08-18T17:11:31.385728
Scroll to Top